ATS 2019 Virtual Final Program

• state the value of a multidisciplinary approach to diagnosis and management of patients with diffuse lung disease in light of new and upcoming recommendations on diagnosis of idiopathic pulmonary fibrosis. This course will review major aspects of thoracic imaging with presentations targeted towards practitioners in the fields of pulmonary and critical care medicine. Dedicated thoracic radiologists will give case-based reviews focusing on the practical aspects of chest imaging. Presentations will be image rich and focus on key imaging findings, differential diagnoses, and potential pitfalls. Topics will cover a broad range of chest disease and will be relevant to trainees, generalists, and specialists, alike. At the conclusion of the course, learners will have increased knowledge about thoracic imaging and be able to apply this knowledge to their respective practices. Chairing: J.P. Kanne, MD, Madison, WI C.C. Wu, MD, Houston, TX 8:00 Large Airways Diseases S. Rossi, MD, Buenos Aires, Argentina 8:30 Small Airways Diseases T.S. Henry, MD, San Francisco, CA 9:00 Pleural Disease C.C. Wu, MD, Houston, TX 9:30 Break 9:45 Solitary Pulmonary Nodule J. Mammarappallil, MD, PhD, Durham, NC 10:15 Lung Cancer Screening M.D. Martin, MD, Madison, WI 10:45 Pulmonary Infections L.H. Ketai, MD, Albuquerque, NM 11:15 Acute Lung Injury K. Batra, MD, Dallas, TX 11:45 LUNCH 12:45 Pulmonary Hypertension M.D. Martin, MD, Madison, WI 1:15 Break 1:30 Multidisciplinary Approach to Diffuse Lung Diseases K.K. Brown, MD, Denver, CO S. Hobbs, MD, Lexington, KY S.D. Groshong, MD, PhD, Denver, CO BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL POSTGRADUATE COURSE CME Credits Available: 6.5 PG6 INTERSTITIAL LUNG DISEASE: CURRENT TRENDS IN DIAGNOSIS AND MANAGEMENT R Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 : Registrants must bring a laptop to the course to view the course material. Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing; Pulmonary Rehabilitation 8:00 a.m. - 4:00 p.m. KBHCCD Room C140/C142 (Level 1) Target Audience Clinicians, nurses, other allied health staff, researchers, investigators in basic and clinic science pertinent to interstitial lung disease, and sponsors for research Objectives At the conclusion of this session, the participant will be able to: • accurately diagnose patients with specific forms of interstitial lung disease; • discuss recent clinical trials in the area of idiopathic pulmonary fibrosis in particular with their patients as well as biomarkers and preclinical interstitial lung abnormalities with patients; • gain competence in their ability to provide evidence based care to patients with ILD via comprehensive management strategies. This course will provide an introduction and update on diagnosis and management of the heterogeneous group of interstitial lung diseases (ILDs) of unknown etiology as well ILD in the setting of connective tissue diseases, vasculitis, and environmental exposures. Idiopathic pulmonary fibrosis (IPF), lymphatic disorders, and granulomatous ILD (hypersensitivity pneumonitis and sarcoidosis) are among the diseases that will be discussed. Genetic factors, precision medicine for diagnosis and treatment as well as newer concepts in the pathogenesis of IPF and novel treatment strategies to modulate pulmonary fibrosis will be discussed. Attendees will be updated on evolving enhanced knowledge in the clinical management of patients with ILD. The importance of making an accurate diagnosis will be demonstrated by live interactions with a panel of experts from multiple disciplines confronted with 3-4 cases unknown to them. This will illustrate multidisciplinary diagnosis (MDD) in action. Additional talks will focus on the symptom managementfor patients with pulmonary fibrosis, preclinical ILD and emerging biomarkers. Chairing: G. Raghu, MD, Seattle, WA L. Richeldi, MD, PhD, Rome, Italy B. Collins, MD, Seattle, WA 8:00 Introduction G. Raghu, MD, Seattle, WA 8:10 ILD Overview B. Collins, MD, Kirkland, WA 8:30 Approach to Diagnosis of IPF, Focus on Recent Recommendations G. Raghu, MD, Seattle, WA 8:50 Imaging: Clues to Diagnosis and New Tools for Assessing Extent of ILD S.L.F. Walsh, MD, PhD, London, United Kingdom 9:10 Histopathology: Differentiating Idiopathic Interstitial Pneumonias from Other Interstitial Pneumonias and Granulomatous ILD K.D. Jones, MD, San Francisco, CA 9:30 Preclinical Interstitial Lung Abnormalities: Can Progression Be Prevented? A. Podolanczuk, MD, New York, NY ATS 2019 • Dallas, TX FRIDAY • MAY 17 5 FRIDAY